Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC By Ogkologos - August 11, 2026 159 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COMMIT study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Maintenance Olaparib in Elderly Patients With a Germline BRCA Mutation and... July 1, 2020 Journalist Is Now Cancer-Free After Receiving Diagnosis On Facebook Live November 1, 2019 These Triplets Were Tired Of Being Mistaken For Each Other. Their... June 14, 2019 Toddler Celebrates 11 Months Cancer-Free In Adorable Dance Video With Dad. October 17, 2019 Load more HOT NEWS 20.° Aniversario de Cancer.Net: Celebramos Nuestra Misión de Brindar Información Confiable... How Cancer Survivors Can Overcome Common Challenges of Exercise After Treatment Survivor Guest Post: Living Breast-less Accepting Help During Cancer Is Hard, But It Can Benefit You...
